Literature DB >> 21671867

D-galactose as a vector for prodrug design.

Daniela Melisi1, Annalisa Curcio, Elvira Luongo, Elena Morelli, Maria Grazia Rimoli.   

Abstract

D-galactose is a simple and natural compound that has mainly been exploited in prodrug strategies. Galactosyl prodrugs can be considered a good approach to reach different goals in clinical drug application, especially when traditional drugs are likely to fail therapeutically owing to reasons such as the lack of site specificity, toxicity, and chemical instability. Indeed, of paramount importance is their ability to increase the selectivity of the parent compound, a phenomenon that helps to reduce the incidence of adverse effects, while preserving intact the pharmacodynamic features of the parent drug. Study results have varied according to the type of linkage between the drug and the hydroxyl group exploited. By working with these parameters, researchers have been able not only to generate selective pharmacological targeting of brain, liver, and cancerous cells, but also to improve cellular permeability as well as the pharmacokinetic profile of parent drugs. This review describes the broad spectrum of possibilities for exploiting D-galactose as a vector for prodrug design and the synthetic strategies that allow its realization.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21671867     DOI: 10.2174/156802611797183258

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  5 in total

1.  Glucose conjugation for the specific targeting and treatment of cancer.

Authors:  Emilia C Calvaresi; Paul J Hergenrother
Journal:  Chem Sci       Date:  2013-06       Impact factor: 9.825

2.  8-Hydroxyquinoline Glycoconjugates: Modifications in the Linker Structure and Their Effect on the Cytotoxicity of the Obtained Compounds.

Authors:  Monika Krawczyk; Gabriela Pastuch-Gawołek; Aleksandra Pluta; Karol Erfurt; Adrian Domiński; Piotr Kurcok
Journal:  Molecules       Date:  2019-11-18       Impact factor: 4.411

3.  Ketogal: A Derivative Ketorolac Molecule with Minor Ulcerogenic and Renal Toxicity.

Authors:  Roberto Russo; Carmen De Caro; Bice Avallone; Salvatore Magliocca; Maria Nieddu; Gianpiero Boatto; Roberta Troiano; Rosario Cuomo; Carla Cirillo; Carmen Avagliano; Claudia Cristiano; Giovanna La Rana; Giovanni Sarnelli; Antonio Calignano; Maria G Rimoli
Journal:  Front Pharmacol       Date:  2017-11-06       Impact factor: 5.810

4.  Preparation and activity of glycosylated acetylsalicylic acid.

Authors:  Gangliang Huang; Hao Cheng; Yang Liu; Jinchuan Hu
Journal:  Saudi Pharm J       Date:  2017-12-05       Impact factor: 4.330

5.  Galactose-modified duocarmycin prodrugs as senolytics.

Authors:  Ana Guerrero; Romain Guiho; Nicolás Herranz; Anthony Uren; Dominic J Withers; Juan Pedro Martínez-Barbera; Lutz F Tietze; Jesús Gil
Journal:  Aging Cell       Date:  2020-03-16       Impact factor: 9.304

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.